Details:
Through the acquisition, Hengkang entered the field of biosynthesis, improved the commercial production capacity of products in the field of biosynthesis, enriched its product pipeline by adding KD-370, a pentavalent vaccine, approved in Japan.
Lead Product(s): KD-370
Therapeutic Area: Infections and Infectious Diseases Product Name: KD-370
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Meiji Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 10, 2023